Akoya Biosciences

AKYA · NASDAQ

Price unavailable right now.

No price history for this range.

About AKYA

Akoya Biosciences, Inc. is a life sciences technology company delivering spatial biology solutions focused on transforming discovery and clinical research. The company is headquartered in Marlborough, Massachusetts and currently employs 205 full-time employees. The company offers comprehensive single-cell imaging solutions that allow researchers to phenotype cells with spatial context and visualize how they organize and interact to influence disease progression and response to therapy. The company offers a full continuum of spatial phenotyping solutions to serve the diverse needs of researchers across discovery, translational and clinical research: PhenoCode Panels and PhenoCycler, PhenoImager Fusion and PhenoImager HT Instruments. Its PhenoCycler platform provides ultra-high parameter biomarker discovery, with the ability to analyze high-plex single-cell resolution across the entire tissue sample. Its PhenoImager platform enables researchers to visualize, analyze, quantify and phenotype cells in situ, in fresh frozen or formalin-fixed paraffin-embedded tissue sections, and tissue microarrays.

Employees
205
Headquarters
Marlborough, Massachusetts
Listed
Apr 16, 2021
Sector
Health Care
Industry
Life Sciences Tools & Services

Leadership

Akoya Biosciences executives
NameTitleSince
Masoud Toloue—2025
Vandana Sriram——
Laurie Churchill——
Brian Keane——

Revenue by product and region

Fiscal year ended Dec 31, 2024: $81.67M total revenue

By product

  • Product$53.03M64.9%
  • Service and other$28.64M35.1%

By region

  • North America$50.86M62.3%
  • EMEA$18.85M23.1%
  • APAC$11.96M14.6%

Similar companies

Companies in the same industry as Akoya Biosciences

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.